Neisseria meningitidis

TRUMENBA safety information

Scroll for Important Safety Information and Indication

  • Severe allergic reaction after a previous dose of Trumenba is a contraindication
  • Individuals with altered immunocompetence may have reduced immune responses to Trumenba
  • In clinical studies, the most common solicited adverse reactions were pain at the injection site (≥85%), fatigue (≥40%), headache (≥35%), muscle pain (≥30%), and chills (≥15%)
  • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Safety and effectiveness has not been established in pregnant women

  • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
  • Approval of Trumenba is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of Trumenba against diverse serogroup B strains has not been confirmed

Please see full Prescribing Information.

Vaccinate with TRUMENBA

Vaccinate with TRUMENBA to help protect 10 through 25 year olds from serogroup B meningococcal disease Vaccinate with TRUMENBA to help protect 10 through 25 year olds from serogroup B meningococcal disease

A collection of services designed to help you and your practice protect against MenB in adolescent and young adult patients 10 through 25 years of age.

Trumenba Home page video block

Only TRUMENBA targets both subfamilies, A and B, of factor H binding protein (fHBP).1

TRUMENBA in your practice

A MenB vaccine series may be administered to individuals aged 16 through 23 years.2

TRUMENBA is available for use in your practice. Follow the simple steps to order TRUMENBA today.

Why adolescents and young adults?

Typical adolescent and young adult behaviors can spread the disease.3

Find out why adolescents and young adults are among the increased risk population.

TRUMENBA clinical studies

TRUMENBA demonstrated cross-coverage against MenB strains expressing both subfamilies, A and B, of fHBP.1

TRUMENBA demonstrated a robust immune response
*Advisory Committee on Immunization Practices.


  • Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2016.
  • MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1177.
  • Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. Updated March 4, 2016. Accessed May 5, 2016.